Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China
Abstract Background Ensuring equal access to affordable, high-quality, and satisfied healthcare for cancer patients is a challenge worldwide. Our study aimed to investigate preferences for public health insurance coverage of new anticancer drugs among non-small cell lung cancer (NSCLC) patients in C...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Public Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12889-024-20951-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594358347497472 |
|---|---|
| author | Jingyi Meng Feifei Yan Maochun Chen Yuchen Ding Zhe Feng Wenzhang Lu Jinsong Geng |
| author_facet | Jingyi Meng Feifei Yan Maochun Chen Yuchen Ding Zhe Feng Wenzhang Lu Jinsong Geng |
| author_sort | Jingyi Meng |
| collection | DOAJ |
| description | Abstract Background Ensuring equal access to affordable, high-quality, and satisfied healthcare for cancer patients is a challenge worldwide. Our study aimed to investigate preferences for public health insurance coverage of new anticancer drugs among non-small cell lung cancer (NSCLC) patients in China. Methods We identified six attributes of new anticancer drugs and adopted a Bayesian-efficient design to generate choice scenarios for a discrete choice experiment (DCE). The one-on-one, face-to-face DCE was conducted in four cities in Jiangsu Province. The mixed logit regression model was used to estimate patient-reported preferences for each attribute. The interaction model was used to investigate preference heterogeneity. Results Data from 486 patients were available for analysis. The most valuable attribute was the out-of-pocket cost if reimbursed (RI = 32.25%), followed by extension of overall survival (RI = 15.99%), and low incidence of serious side effects (RI = 14.45%). Patients had the highest willingness to pay for the comparative 9-month’ extension of overall survival. Patients with advanced NSCLC were more likely to expect new anticancer drugs could improve HRQoL (p < 0.01) and require fewer out-of-pocket costs (p < 0.01). Older patients and patients with low income cared more about the out-of-pocket costs (p < 0.001). Conclusion Health insurance policymakers need to consider the affordability, comparative survival benefits, comparative safety, and comparative patient-reported outcomes of new anticancer drugs. The findings also highlight the need to ensure affordability for older patients, low-income patients, and patients with advanced cancer. |
| format | Article |
| id | doaj-art-b0a213608ec340778e5612af24b43534 |
| institution | Kabale University |
| issn | 1471-2458 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Public Health |
| spelling | doaj-art-b0a213608ec340778e5612af24b435342025-01-19T12:41:37ZengBMCBMC Public Health1471-24582025-01-0125111110.1186/s12889-024-20951-6Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in ChinaJingyi Meng0Feifei Yan1Maochun Chen2Yuchen Ding3Zhe Feng4Wenzhang Lu5Jinsong Geng6Medical School of Nantong UniversityMedical School of Nantong UniversityDepartment of General Surgery, Affiliated Dongtai Hospital of Nantong UniversityDepartment of Radiology, Affiliated Hospital of Nantong UniversityMedical School of Nantong UniversityDepartment of Respiratory, Affiliated Hospital of Nantong UniversityMedical School of Nantong UniversityAbstract Background Ensuring equal access to affordable, high-quality, and satisfied healthcare for cancer patients is a challenge worldwide. Our study aimed to investigate preferences for public health insurance coverage of new anticancer drugs among non-small cell lung cancer (NSCLC) patients in China. Methods We identified six attributes of new anticancer drugs and adopted a Bayesian-efficient design to generate choice scenarios for a discrete choice experiment (DCE). The one-on-one, face-to-face DCE was conducted in four cities in Jiangsu Province. The mixed logit regression model was used to estimate patient-reported preferences for each attribute. The interaction model was used to investigate preference heterogeneity. Results Data from 486 patients were available for analysis. The most valuable attribute was the out-of-pocket cost if reimbursed (RI = 32.25%), followed by extension of overall survival (RI = 15.99%), and low incidence of serious side effects (RI = 14.45%). Patients had the highest willingness to pay for the comparative 9-month’ extension of overall survival. Patients with advanced NSCLC were more likely to expect new anticancer drugs could improve HRQoL (p < 0.01) and require fewer out-of-pocket costs (p < 0.01). Older patients and patients with low income cared more about the out-of-pocket costs (p < 0.001). Conclusion Health insurance policymakers need to consider the affordability, comparative survival benefits, comparative safety, and comparative patient-reported outcomes of new anticancer drugs. The findings also highlight the need to ensure affordability for older patients, low-income patients, and patients with advanced cancer.https://doi.org/10.1186/s12889-024-20951-6Patients’ preferencesHealth insuranceAnticancer drugsDiscrete choice experiment |
| spellingShingle | Jingyi Meng Feifei Yan Maochun Chen Yuchen Ding Zhe Feng Wenzhang Lu Jinsong Geng Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China BMC Public Health Patients’ preferences Health insurance Anticancer drugs Discrete choice experiment |
| title | Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China |
| title_full | Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China |
| title_fullStr | Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China |
| title_full_unstemmed | Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China |
| title_short | Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China |
| title_sort | preferences for public health insurance coverage of new anticancer drugs a discrete choice experiment among non small cell lung cancer patients in china |
| topic | Patients’ preferences Health insurance Anticancer drugs Discrete choice experiment |
| url | https://doi.org/10.1186/s12889-024-20951-6 |
| work_keys_str_mv | AT jingyimeng preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina AT feifeiyan preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina AT maochunchen preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina AT yuchending preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina AT zhefeng preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina AT wenzhanglu preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina AT jinsonggeng preferencesforpublichealthinsurancecoverageofnewanticancerdrugsadiscretechoiceexperimentamongnonsmallcelllungcancerpatientsinchina |